Vault CTMS simplifies end-to-end trial management for greater visibility and speed in trials<\/em><\/p>\n BARCELONA, Spain \u2014 11 Nov., 2020 \u2014<\/strong> As the need to improve efficiency and speed in trials grows, more than 75 organizations, including six of the top 20 pharmaceutical companies, are unifying clinical information and processes with Veeva Vault CTMS<\/a>. More emerging biotechs and global organizations have adopted the modern cloud application from Veeva Systems<\/a> (NYSE: VEEV) for greater visibility and faster execution in trials. Sponsors and clinical research organizations (CROs) are using Vault CTMS to manage nearly 50,000 clinical trials across all study phases. <\/p>\n \u201cThe widespread use of siloed systems and spreadsheets to manage clinical trials have been slowing down studies for years,\u201d said Henry Galio, senior director, Veeva Vault CTMS. \u201cCompanies are standardizing on Veeva Vault CTMS for real-time insights into study status to proactively manage trials and speed research.\u201d<\/p>\n Legacy systems are difficult to use and configure, adding complexity to trials, and slowing study execution. Companies that use modern CTMS applications report better compliance with standards, greater visibility, and improved governance and oversight than those using manual-based spreadsheets or internally developed systems to manage studies.1<\/small><\/small> <\/p>\n Vault CTMS streamlines end-to-end trial management for improved collaboration and increased transparency across trials. Sponsors and CROs can proactively identify obstacles and take corrective action to avoid delays. Now clinical teams can keep trials on track and better meet study milestones while maintaining compliance with ICH\/GCP guidelines.<\/p>\n Veeva continues to bring innovations to market that simplify clinical processes. Over the last year, Veeva has added new capabilities to help customers proactively manage trials and adapt quickly to changes, including:<\/p>\n Vault CTMS is part of Veeva Vault Clinical Operations Suite<\/a>, enabling sponsors and CROs to seamlessly share information and documents across CTMS, eTMF, and study start-up for better collaboration and increased efficiency throughout the study lifecycle. <\/p>\n AstraZeneca discusses the positive impact of a unified clinical landscape on global study execution at the Veeva R&D and Quality Summit, register for the on-demand session at veeva.com\/rdsummit<\/a>. <\/p>\n Additional Information<\/strong> About Veeva Systems<\/strong> Forward-looking Statements<\/strong> ###<\/p>\n Contact:<\/strong><\/p>\n Veeva Systems\n
\nFor more on Veeva Vault CTMS, visit: veeva.com\/CTMS<\/a>
\nConnect with Veeva on LinkedIn: linkedin.com\/company\/veeva-systems<\/a>
\nFollow @veeva_eu on Twitter: twitter.com\/veeva_eu<\/a>
\nLike Veeva on Facebook: facebook.com\/veevasystems<\/a><\/p>\n
\nVeeva Systems Inc. is a leader in cloud solutions\u2014including data, software, and services\u2014for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world’s largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com\/eu<\/a>.<\/p>\n
\nThis release contains forward-looking statements, including the market demand for and acceptance of Veeva\u2019s products and services, the results from use of Veeva\u2019s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva\u2019s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva\u2019s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva\u2019s financial results are included under the captions, \u201cRisk Factors\u201d and \u201cManagement\u2019s Discussion and Analysis of Financial Condition and Results of Operations,\u201d in the company\u2019s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company\u2019s website at veeva.com<\/a> under the Investors section and on the SEC\u2019s website at sec.gov<\/a>. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.<\/p>\n
\npr@veeva.com<\/a><\/p>\n